In conjunction with Eli Lilly and Co.'s recent FDA approval of Amyvid (florbetapir), Safeguard Scientifics Inc. received a $5.6 million earn-out payment from its investment in Avid Radiopharmaceuticals Inc. before Lilly purchased the biotech.